We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Automated Free Testosterone Test Advances Diagnostic Capabilities for Androgen Disorders

By LabMedica International staff writers
Posted on 17 Jan 2025
Print article
Image: The state-of-the-art assay is processed the random-access iSYSTM or i10 TM instruments (Photo courtesy of EUROIMMUN)
Image: The state-of-the-art assay is processed the random-access iSYSTM or i10 TM instruments (Photo courtesy of EUROIMMUN)

A state-of-the-art assay offers direct measurement of free testosterone levels in a single test, significantly improving diagnostic capabilities for conditions such as hypogonadism, impotence, polycystic ovarian syndrome (PCOS), and other androgen-related disorders.

Revvity, Inc. (Waltham, MA, USA) has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s (Lübeck, Germany) automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This groundbreaking test is the first of its kind to receive FDA approval for the direct quantitative measurement of free testosterone levels, marking a major step forward in diagnosing androgen disorders. The advanced assay operates on the company’s random-access iSYSTM or i10TM instruments, offering quick turnaround times and high throughput testing with minimal technician training required, while ensuring exceptional accuracy and reliability.

This FDA-cleared ChLIA assay provides rapid results for the direct quantitative measurement of free testosterone in human serum or plasma. The first result is available in just 48 minutes, with an estimated throughput of nearly 60 tests per hour on EUROIMMUN’s ChLIA platforms. The use of monoclonal antibodies guarantees specificity and consistent performance across test batches.

"Laboratory customers have been asking for a user-friendly FDA-cleared test, on a random-access platform, for direct measurement of free testosterone," said Jonathan Friend, general manager at Revvity’s EUROIMMUN US. "This clearance reinforces our commitment to expanding the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions with assays that serve diverse patient populations across all demographics.”

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
Silver Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Autoimmune Disease Test
Anti-Centromere B ELISA Test

Print article

Channels

Microbiology

view channel
Image: The breakthrough system offers a faster way to diagnose bloodborne infections (Photo courtesy of Melio)

Culture-Free Platform Rapidly Identifies Blood Stream Infections

Neonatal sepsis is a life-threatening condition that results from bloodstream infections in newborns under 28 days old. Due to their immature immune systems, newborns are especially vulnerable to infections.... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.